Archives
-
SmD2 Acetylation Links Splicing and PARP Sensitivity
2026-10-05
A 2024 Nature Communications study identifies acetylation-dependent control of the spliceosome protein SmD2 as a regulator of cassette exon usage, DNA repair, and PARP inhibitor sensitivity in hepatocellular carcinoma. The findings connect spliceosome regulation with BRCA1/FANC expression and support further evaluation of combined HDAC and PARP inhibition, while remaining preclinical and model-dependent.
-
TRPV1/TRPA1 Control of Nasal TSLP Production
2026-10-05
The reference study connects TRPV1 and TRPA1 activation in nasal epithelial cells with calcium-dependent NFAT signaling and increased TSLP production. Its combined use of pharmacological perturbation, siRNA, calcium chelation, inflammatory-factor profiling, and NFAT localization provides a useful framework for interpreting epithelial ion-channel signaling while leaving important questions about in vivo relevance unresolved.
-
ATRA Sensitizes Ovarian Cancer to PARP Inhibition
2026-10-04
A 2025 Molecular Cancer Therapeutics study reports that all-trans retinoic acid can reduce cisplatin-associated resistance to PARP inhibition in epithelial ovarian cancer models. Its findings connect this effect with suppression of a resistance-associated ALDH1A1–NAMPT–PARP1–CHK1 program and reduced intracellular NAD+, supporting further evaluation of ATRA combined with niraparib as a maintenance strategy.
-
Alkaline Phosphatase Substrate Kit Overview
2026-10-03
The Alkaline Phosphatase (AP) Substrate Test Kit, SKU K4151, is an APExBIO BCIP/NBT chromogenic product described for visual alkaline phosphatase activity detection. No matched paper evidence was available, so application-specific performance and suitability remain unverified.
-
KU-60019: Turning ATM Inhibition Into Insight
2026-10-02
KU-60019 offers a selective way to interrogate ATM-dependent DNA damage responses in glioma. This thought-leadership analysis connects its mechanistic profile with radiation biology, migration and invasion assays, formulation strategy, translational model selection, and a carefully bounded lesson from recent HBoV epigenetics research.
-
Mouse Tissue Lysis Kit K1038: Practical Workflow
2026-10-01
The Mouse Tissue Lysis Kit K1038 provides a direct route from mouse tail, toe, or ear tissue to a lysate suitable for PCR-based genotyping and DNA analysis, without a separate extraction or purification step. It is intended for molecular biology research and assay development, not diagnostic, clinical, or medical sample preparation.
-
Resazurin Cell Viability Assay in Bone Research
2026-10-01
The Resazurin Cell Viability Assay Kit can serve as more than a routine endpoint in bone research: it helps distinguish treatment-related cytotoxicity from genuine changes in Wnt-driven osteoblast biology. This article develops a decision framework for fluorescence, colorimetric, and orthogonal assay interpretation.
-
TCF25, Lysosomal Acidification, and Nutrient Stress
2026-09-30
Ren et al. identify TCF25 as a nutrient-stress regulator that connects V-ATPase-dependent lysosomal acidification with the transition from adaptive autophagy to lysosome-dependent cell death during glucose starvation. The study combines genome-wide CRISPR-Cas9 screening, mechanistic validation, and a mouse ischemia-reperfusion model to define TCF25 as a potential target in metabolic and ischemic injury.
-
SLC2A5 Fructose Metabolism in Primary CNS Lymphoma
2026-09-30
This study uses single-cell RNA and B-cell receptor profiling to identify SLC2A5-mediated fructose metabolism as a shared metabolic vulnerability in primary central nervous system lymphoma and tumor-supportive macrophages. Its genetic and pharmacological validation links glucose-poor, hypoxic tumor microenvironments to lymphoma growth and T-cell dysfunction, while suggesting a framework for studying tumor–microenvironment metabolic interactions.
-
AG-126: A Causal Assay Map for ERK Biology
2026-09-29
AG-126 and Tyrphostin AG-126 provide a practical way to test ERK1/2 signaling alongside cell-type-specific mechanisms of repetitive behavior. This article distinguishes established evidence from exploratory ASD assay design and outlines a rigorous workflow for interpreting phosphorylation, cytokine, and circuit-level readouts.
-
Vemurafenib in BRAF-Mutant Melanoma Research
2026-09-29
Vemurafenib (PLX4032) is a practical BRAF V600-mutant probe for linking genotype, MAPK signaling, and melanoma cell proliferation inhibition. This workflow-focused guide covers dosing, controls, resistance modeling, solubility, and multi-omics assay design while emphasizing the compound’s paradoxical activity in BRAF-wild-type cells.
-
REV1–DHX36 Control of G-Quadruplex Replication
2026-09-28
A 2026 Nucleic Acids Research study identifies a direct REV1–DHX36 interaction that coordinates G-quadruplex unwinding, replication-fork progression, and suppression of single-stranded DNA gaps. The work reframes REV1 as both a translesion-synthesis scaffold and a regulator of helicase activity during G4 stabilization, providing a mechanistic framework for studying replication stress and DNA damage response signaling.
-
How CXCR4 Controls Platelet Entry into Tumors
2026-09-28
The study describes platelet entry into tumors as a regulated trafficking process, not simply a consequence of vascular leakage. It identifies stromal CXCL12–CXCR4 signaling, platelet FAK and PECAM-1, and distinct granule-release pathways as separable controls of platelet migration and tumor growth.
-
Affinity-Purified Goat Anti-Rabbit IgG (H+L) Guide
2026-09-27
Connect apoptosis and pyroptosis experiments to clear protein-detection workflows using an HRP-labeled secondary antibody for rabbit primaries. This guide covers Western blot, ELISA, and tissue staining, with practical starting conditions and troubleshooting advice for studies of hyperthermia–cisplatin responses.
-
BMN 673 (Talazoparib): PARP1/2 Inhibitor
2026-09-26
BMN 673 (Talazoparib) is a potent PARP1/2 inhibitor used in research on DNA repair deficiency targeting. Its trapping activity is relevant to homologous recombination-deficient models, but reported biochemical potency and class-level mechanism findings should not be mistaken for a validated protocol or a talazoparib-specific result in every model.